Table 1 The details of FIGHT and LIVE trials
From: Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
FIGHT | LIVE | |||
|---|---|---|---|---|
Liraglutide (N = 154) | Placebo (N = 146) | Liraglutide (N = 122) | Placebo (N = 119) | |
Genaral data | ||||
Age | 62 (52–68) | 61 (51–67) | 65 ± 9.2 | 65 ± 10.7 |
Male | 123 (80%) | 113 (77%) | 109 (89%) | 106 (89%) |
BMI (kg/m2) | 31 (26–36) | 33 (25–38) | 28.0 ± 3.8 | 29.8 ± 4.6 |
Functional measures | ||||
6MWT (m) | 234 (143–313) | 212 (141–311) | 453 ± 104 | 441 ± 122 |
NYHA | ||||
I | 4 (3%) | 8 (5%) | 36 (30%) | 35 (29%) |
II | 49 (32%) | 36 (25%) | 65 (53%) | 64 (54%) |
III | 93 (60%) | 96 (66%) | 17 (14%) | 16 (13%) |
IV | 8 (5%) | 6 (4%) | 4 (3%) | 4 (3%) |
Physical examination | ||||
SBP | 108 (99–120) | 108 (99–118) | 128 ± 20 | 127 ± 18 |
HR | 75 (68–85) | 76 (68–88) | 67 ± 10 | 67 ± 11 |
Medical history | ||||
T2DM | 91 (59%) | 87 (60%) | 39 (32%) | 35 (29%) |
AF | 74 (48%) | 70 (48%) | 34 (28%) | 34 (29%) |
Ischemic heart disease | 133 (86%) | 113 (77%) | 72 (59%) | 73 (61%) |
Laboratory measures | ||||
NT-proBNP (pg/mL) | 1936 (1075–4231) | 2083 (1020–4333) | 413 (208–926) | 388 (153–880) |
HbA1c (%) | 6.6 (6.6–7.6) | 6.7 (5.9–7.9) | 5.9 ± 0.7 | 6.0 ± 0.8 |
Echocardiographic data | ||||
LVEF (%) | 25 (20–33) | 25 (19–32) | 33.7 ± 7.6 | 35.4 ± 9.4 |
LVESV (mL) | 104 (78–130) | 100 (80–1330 | 111 ± 60 | 109 ± 78 |
LVEDV (mL) | 140 (112–173) | 137 (115–174) | 163 ± 71 | 165 ± 111 |
E/e' | 22 (17–28) | 23 (18–30) | 12.6 ± 6.0 | 11.7 ± 5.5 |
Heart failure medications | ||||
ACEI/ARB | 112 (73%) | 104 (71%) | 118 (97%) | 115 (97%) |
β-Blocker | 143 (93%) | 139 (95%) | 113 (93%) | 108 (91%) |
Aldosterone recepter antagonist | 88 (57%) | 89 (61%) | 59 (48%) | 54 (45%) |
Loop diuretic | 151 (98%) | 146 (100%) | 90 (74%) | 90 (76%) |
Lipid-lowering agent | 110 (71%) | 110 (75%) | 96 (79%) | 92 (77%) |
Treatmen effect | ||||
LVEF | − 0.1 (− 2.3–2.1) | − 0.8 (− 2.1–0.5) | ||
LVESV | 5 (− 2.6–12.7) | 2.6 (− 1.2–6.4) | ||
LVEDV | 6.7 (− 2.6–16) | 3.4 (− 2.3–9.2) | ||
6MWT | 5 (− 29–39) | 24 (2–47) | ||
NT-proBNP (pg/mL) | − 155 (− 1368–1058) | − 140 (− 317–37) | ||
HbA1c (%) | − 0.33 (− 0.67–0) | − 0.4 (− 0.5– − 0.3) | ||
HR | − 1.6 (− 4.8–1.6) | 7 (5–9) | ||